STAT3 and non-small cell lung carcinoma: The majority of NSCLC patients exhibit abnormally high levels of signal transducer and activator of transcription 3 (STAT3) overexpression, which is an essential component of the JAK–STAT pathway (Mohrherr et al. 2020).